|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process: John Brebner, Karen Green, MD, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:
Dr Chlebowski — Consulting Fees: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, Pfizer Inc; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation. Dr Cuzick — Consulting Fees: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Pfizer Inc. Dr Dickler — Consulting Fees: AstraZeneca Pharmaceuticals LP, Genentech BioOncology; Contracted Research: Genentech BioOncology; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP. Dr Giordano — No financial interests or affiliations to disclose. Dr Jahanzeb — Contracted Research: Amgen Inc, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis; Speakers Bureau: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Sanofi-Aventis; Advisory Boards: AstraZeneca Pharmaceuticals LP, Easi Pharmaceuticals, Eli Lilly and Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
 |
 |
EDITOR
Neil Love, MD
INTERVIEWS
Sharon Giordano, MD, MPH
- Select publications
Rowan T Chlebowski, MD, PhD
- Select publications
Tumor Panel Case Discussion
- Select publications
INTERVIEWS (continued)
Jack Cuzick, PhD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
